Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study

Background: The effects of dipeptidyl peptidase-4 inhibitors (DPP4Is) on joint pain have been controversial. Objective: To assess the comparative musculoskeletal (MSk) risk of DPP4Is vs. non-DPP4Is. Methods: This study used a national claims database from January 2007 to December 2014. Exposure incl...

Full description

Bibliographic Details
Main Authors:	Taehwan Park, Maureen Bresnahan, Scott K. Griggs, Jiajing Chen, Alex H. Cho, Yolene Gousse, Mark Feinglos
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Exploratory Research in Clinical and Social Pharmacy
Subjects:	DPP4 inhibitors Comparative risk Musculoskeletal adverse reactions Pharmacoepidemiology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667276621000226

Similar Items

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022-09-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
by: Bárbara Torrecillas-Baena, et al.
Published: (2023-07-01)

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
by: Jie Huang, et al.
Published: (2022-03-01)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
by: Ruili Yin, et al.
Published: (2022-05-01)

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
by: Yu Tian, et al.
Published: (2023-12-01)

Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
by: Yumi Harano, et al.
Published: (2023-06-01)

Progress on application of dipeptidyl peptidase Ⅲ in the treatment of sepsis
by: WANG Yingchen, SUN Liqun
Published: (2023-01-01)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
by: James M. Henderson, et al.
Published: (2021-11-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
by: Kaisa Tasanen, et al.
Published: (2019-06-01)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)
by: E. A. Ortenberg, et al.
Published: (2022-06-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Identification of Dipeptidyl Peptidase (DPP) Family Genes in Clinical Breast Cancer Patients via an Integrated Bioinformatics Approach
by: Tak-Kee Choy, et al.
Published: (2021-07-01)

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
by: Masanori Hirose, et al.
Published: (2017-12-01)

Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas
by: Ivana Matrasova, et al.
Published: (2017-09-01)

Dipeptidyl Amino-Peptidase 3 (DPP3) as an Early Marker of Severity in a Patient Population with Cardiogenic Shock
by: Pasquale Innelli, et al.
Published: (2023-04-01)

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
by: Badrud Duza Mohammad, et al.
Published: (2022-09-01)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017-07-01)

Molecular Docking of Compounds in Moringa oleifera Lam with Dipeptidyl Peptidase-4 Receptors as Antidiabetic Candidates
by: Indah Permata Rendi, et al.
Published: (2021-12-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021-12-01)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
by: Fen Cao, et al.
Published: (2021-08-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: An in silico approach
by: Selvaraj Gurudeeban, et al.
Published: (2012-10-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Analysis of Citrus Bioflavonoid Content and Dipeptidyl Peptidase-4 Inhibitory Potential of Commercially Available Supplements
by: Ankit Gupta, et al.
Published: (2022-07-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Survey of Dipeptidyl Peptidase III Inhibitors: From Small Molecules of Microbial or Synthetic Origin to Aprotinin
by: Marija Abramić, et al.
Published: (2022-05-01)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
by: Alba Sebastián-Martín, et al.
Published: (2022-08-01)

Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases
by: Agnieszka Ługowska, et al.
Published: (2021-02-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Urinary dipeptidyl peptidase-4 is a useful marker for tubulitis, and it is released from the tubular cells of kidney transplant recipients
by: Atsushi Yamagishi, et al.
Published: (2022-07-01)

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo
by: Fenfen Yan, et al.
Published: (2020-01-01)

Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
by: Jingjing Wang, et al.
Published: (2019-01-01)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
by: Ghadeer K. Dawwas, et al.
Published: (2018-07-01)

The purification and identification of antioxidants and dipeptidyl peptidase IV inhibitory peptides from whey protein hydrolysates
by: Zheng Yuanrong, et al.
Published: (2022-12-01)

Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
by: Maneesha Khalse, et al.
Published: (2020-01-01)